ClinicalTrials.gg
Enrolling by invitationNCT07949747Updated Nov 19, 2026

Evaluating Pulsed Dye Laser Treatment Parameters on Clearance of Vascular Indications

An interventional study of Laser with DCD Pre- and Post-Cooling and Laser with Standard DCD Pre-Cooling Only in Rosacea, Scars and Port Wine Capillary Malformations, sponsored by University of California, Irvine. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by University of California, Irvine · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jul 2026, registered Nov 2026).
Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 147 studies in Rosacea with a site in United States — 11 open to participants now, 12 under way, none of them phase 3. Rosacea · United States.

Planned enrollment
99th of 139
25 · median 70
Started
2026
with 3 others
No phase
25 of 147
7 open now
Primary completion
2028-12
later than 10 of 11 live
Registered
146th of 147
by date
Lead sponsor
3 of 147
University of California, Irvine

Among the 147 studies in Rosacea with a site in United States, this one is the 99th largest by planned enrollment of the 139 interventional ones that give a count, is one of 4 that started in 2026, is one of 25 with no phase, reaches primary completion later than 10 of the 11 other live ones, and was the 146th registered.

Rosacea

234 studies on the registry are indexed under Rosacea; 24 are open to participants now.

Browse Rosacea studies →

Open to participants now

11 of the 147 studies in Rosacea with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Rosacea studies recruiting now, 10 (59%) set no upper age limit and 6 (35%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies in Rosacea with a site in United States, or all of them as a file.
02

Study summary

The goal of this prospective clinical study is to evaluate pulsed dye laser treatment parameters on the clearance of vascular indications, including rosacea and port wine capillary malformations. The main question it aims to answer is:

- Does the use of post-cooling, compared with no post-cooling, affect patient-reported pain scores and treatment outcomes after one treatment session?

Participants will:

  • Receive PDL treatment according to the study protocol.
  • Complete all required follow-up visits and questionnaires.
  • Undergo OCT imaging assessments, as applicable to the study protocol.
Read the detailed description

This is an exploratory pilot study. The purpose of this research is to understand how to best use the Vbeam Pro Laser System for the treatment of vascular indications, including rosacea and port wine capillary malformations. The present protocol for this pilot study provides a critical pathway to implement a comparison of these laser settings. The qualitative measurements of improvement and tolerability will be quantified using questionnaires. Key characteristics will be summarized for all participants and tabulated by skin condition. Assessment of efficacy will occur after 1 treatment session.

03

Conditions studied

  • Rosacea
  • Scars
  • Port Wine Capillary Malformations

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to understand and carry out subject instructions
  • Subjects 18 years and older, with vascular conditions of interest (e.g., rosacea, port wine capillary malformations, angiomas, red scars, and other vascular malformations)
  • Subjects in good health
  • Subjects with Fitzpatrick skin types I-IV
  • Understands and accepts the obligation not to undergo any other procedures in the areas to be treated through the follow-up period
  • Willingness and ability to comply with protocol requirements including returning for follow-up visits and abstaining from exclusionary procedures for the duration of the study
  • Willingness and ability of participant to provide written and HIPAA authorization prior to performance of any study-related procedure.
  • For a small number of subjects who are already undergoing clinical evaluation or treatment at the study site, they may also be asked to undergo laser treatment on a designated test area of skin that is free from active dermatologic disease.
  • A subset of healthy patients with no dermatological conditions or patients with dermatological conditions with areas of unaffected skin who are willing to undergo treatment on unaffected skin as test areas.

Exclusion criteria

Exclusion Criteria:

  • Inability to understand and/or carry out instructions
  • People who are known to be pregnant or currently breastfeeding
  • Cognitively impaired/medically incapacitated
  • Inability to follow-up appropriately
  • Fitzpatrick skin types V and VI
  • Inability to understand the protocol or to give
  • Presence of an active systemic or local skin disease that may affect wound healing
  • Open wounds in the areas to be treated
  • Participants with photosensitive skin
  • Concurrent therapy that, in the investigator's opinion, would interfere with the study
  • Pre-medical students, dermatology residents, and dermatology faculty or staff
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Outcomes assessor)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Post-Cooling

    Device: Laser with DCD Pre- and Post-Cooling

  • Active comparator
    No Post-Cooling (Control)

    Device: Laser with Standard DCD Pre-Cooling Only

Interventions

  • DeviceLaser with DCD Pre- and Post-Cooling

    Study subject will undergo informed consent procedure, eligibility screening, and enrollment to receive treatment to one or more treatment areas depending on the presenting condition and principal investigator assessment. Study subject may receive 1-3 treatments within the study with 4-12 weeks between each treatment visit. Two test areas will be determined in the area(s) of the vascular condition. Each lesion will serve as its own control, since it is divided in half and each side receives a different set of laser settings. The following laser settings will be applied: Area 1: Spot size 7-15mm; pulse duration 1.5-10 ms; fluence 5-8 j/cm2; cooling settings 10-30/20-30/10-20 ms

  • DeviceLaser with Standard DCD Pre-Cooling Only

    Study subject will undergo informed consent procedure, eligibility screening, and enrollment to receive treatment to one or more treatment areas depending on the presenting condition and principal investigator assessment. Study subject may receive 1-3 treatments within the study with 4-12 weeks between each treatment visit. Two test areas will be determined in the area(s) of the vascular condition. Each lesion will serve as its own control, since it is divided in half and each side receives a different set of laser settings. The following laser settings will be applied: Area 2: Spot size 7-15mm; pulse duration 1.5-10 ms; fluence 5-8 j/cm2; cooling settings 10-30/20-30/0 ms

06

What researchers measure

Primary outcomes

  1. The Effect of Pre- and Post-Cooling on Patient Reported Discomfort as Evaluated by Responses to Two-Part Post-Treatment Questionnaire

    Patients will have a portion of their treatment area(s) treated with both pre-cooling and post-cooling bursts. Note that pre-cooling (a cooling burst delivered immediately prior to the laser pulse) will be used for all treatments across all patients. A difference in tolerability is defined as a difference in at least 1 between the two treatments. The questionnaire assesses the following (only part 1 is used for tolerability): * Part 1 of questionnaire: Immediately following each treatment session, patients will rate their pain/discomfort using a 0-10 scale (0 meaning no pain, 10 meaning severe pain). A difference in tolerability between types of treatment will be considered a difference in 1 or more on this scale. * Part 2 of questionnaire: Patient will be contacted up to 72 hours after treatment to report potential development of adverse effects including swelling, bruising, scabbing, and blistering on a 0-4 scale (0 meaning no effects, 4 meaning severe effects).

    Time frame: From date of first treatment until study completion, assessed up to 52 weeks.

  2. Patient-Reported Evaluation of Improvement as Assessed by Participant Questionnaire

    At the participants' final follow-up visit, they will complete a final questionnaire to assess if there is any difference in improvement between treatment area(s). Patient-reported improvement will be defined as any positive change in appearance, texture and/or global improvement score greater than zero.

    Time frame: From date of first treatment until study completion, assessed up to 52 weeks.

  3. Blinded Physician Evaluation

    Blinded physicians will assess whether there is any difference in improvement between treatment areas(s).

    Time frame: Up to 52 weeks.

  4. Safety and Adverse Events Documented by The Clinician and Self-Reported by The Patient

    Adverse events will be tabulated by type, frequency, severity, treatment relationship, actions taken, and outcome. By the treating physician: Skin response will be assessed immediately after treatment and at follow-up visits. Immediate and long-term adverse effects will be documented by the treating physicians during all treatment and follow-up visits. By the patient: To measure long-term adverse effects, the patient will complete a form at each follow-up visit assessing the following: change in color of the unaffected skin surrounding the treated area (lighter, darker, no change), formation of new scars (yes, no), and other side effects (free response). To measure short-term adverse effects, the patient will complete Part 2 of the post-treatment questionnaire within 72 hours of treatment, which evaluates swelling, bruising, scabbing, and blistering.

    Time frame: From date of first treatment until study completion, assessed up to 52 weeks.

Other outcomes

  1. Exploratory Optical Coherence Tomography (OCT) Assessment of Treatment Response

    Additional exploratory efficacy may be assessed using OCT imaging data. These evaluations will occur within the clinical setting following completion of the treatment series.

    Time frame: From date of first treatment until study completion, assessed up to 52 weeks.

07

Study locations

1 site
08

References and documents

Publications

  • Greve B, Hammes S, Raulin C. The effect of cold air cooling on 585 nm pulsed dye laser treatment of port-wine stains. Dermatol Surg. 2001 Jul;27(7):633-6. doi: 10.1046/j.1524-4725.2001.00352.x. PubMed 11442613 ↗
  • Waldorf HA, Alster TS, McMillan K, Kauvar AN, Geronemus RG, Nelson JS. Effect of dynamic cooling on 585-nm pulsed dye laser treatment of port-wine stain birthmarks. Dermatol Surg. 1997 Aug;23(8):657-62. doi: 10.1111/j.1524-4725.1997.tb00385.x. PubMed 9256912 ↗
  • Wang JV, Bajaj S, Himeles JR, Geronemus RG. Clinical and Optical Coherence Tomography Correlation of Vascular Conditions Treated With a Novel, Variable-Sequenced, Long-Pulsed, 532 and 1,064 nm Laser With Cryogen Spray Cooling. Dermatol Surg. 2024 Mar 1;50(3):277-281. doi: 10.1097/DSS.0000000000004057. Epub 2023 Dec 12. PubMed 38085090 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Dec 2028, 29 months after the start.

Of 42 interventional studies with no phase under Rosacea, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 29. This study's planned 29 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2026
First posted
Nov 19, 2026
StartActual
Jul 6, 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07949747
Collaborators
Candela Corporation
Responsible party
Kristen Kelly (Professor and Chair of Dermatology, University of California, Irvine) — Principal investigator
First posted
Nov 19, 2026
Start date
Jul 6, 2026
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 19, 2026

Study contacts

Kristen Kelly, MD
principal investigator · University of California, Irvine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion